Dr. Choueiri on Expanding the Therapeutic Armamentarium in mRCC | OncLive

Dr. Choueiri on Expanding the Therapeutic Armamentarium in mRCC

August 3, 2020

Toni K. Choueiri, MD, discusses current and emerging treatment options for patients with metastatic renal cell carcinoma.

Toni K. Choueiri, MD, director of the Lank Center for Genitourinary Oncology, director of the Kidney Cancer Center, and senior physician at Dana-Farber Cancer Institute, as well as the Jerome and Nancy Kohlberg chair and professor of medicine at Harvard Medical School, discusses current and emerging treatment options for patients with metastatic renal cell carcinoma (mRCC).

Now, the field of mRCC is catering to an era of combination therapies where single-agent TKIs are being given less often, says Choueiri. Several regimens have received regulatory approval from the FDA over the past few years, such as nivolumab (Opdivo) and ipilimumab (Yervoy), as well as axitinib (Inlyta) in combination with the PD-1 inhibitor pembrolizumab (Keytruda) or avelumab (Bavencio), adds Choueiri. The field also has the single-agent TKI cabozantinib (Cabometyx), which showed superiority over sunitinib (Sutent) in the CABOSUN trial.

Mostly, therapies for metastatic disease are still evolving, as trials have finished accrual and are reading out or are about to be read out, says Choueiri; depending on the data, more options may be added to this list of available options, concludes Choueiri.


x